Navigation Links
Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
Date:9/30/2009

given to CVD patients in combination with statins. ApoA-I therapy has the potential to reduce the overall cost of cardiovascular disease, which is estimated in the U.S. at US $475 billion annually, by 5% to 16%.

Resverlogix is also pleased to announce that it will host a live teleconference today, September 29, 2009 at 1:00 pm Eastern/11:00 am Mountain time. The purpose of the teleconference is to discuss the top line results of this clinical trial. The dial-in numbers for this event are toll free 1-800-319-4610 and international 1-604-638-5340. A link for this webcast is posted onto the homepage of Resverlogix's website and can be accessed from the following address http://services.choruscall.com/links/resverlogix090928.html. The webcast will be available on the Resverlogix website for replay for a period of 45 days after the event.

About RVX-208

RVX-208, a novel small molecule therapeutic that facilitates endogenous ApoA-I production, is positioned to be one of the most promising emerging drugs in the treatment of atherosclerosis. To the Company's knowledge RVX-208 is the only novel small molecule that is specifically designed to increase ApoA-I production and thereby raise HDL levels thus enhancing HDL functionality to augment reverse cholesterol transport (RCT). RCT is a pathway by which accumulated cholesterol is transported from the arterial wall to the liver for excretion, thus preventing atherosclerosis.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as Acute Coronary
'/>"/>

Resverlogix Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
2. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
3. Resverlogix Provides Quarterly Update
4. Resverlogix Board of Directors Update
5. Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
6. Resverlogix Announces Closing of Debt Redemption
7. Resverlogix Eliminates Sixty Percent of Remaining Debt
8. Resverlogix Issues a Management Statement
9. Resverlogix Board of Directors Update
10. Resverlogix Notice of Conference Call & Webcast
11. Jan Gray Joins Resverlogix Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 The largest international professional organization ... and therapeutic derivatives thereof has endorsed an educational ... about the challenges of adulterated herb and botanical ... The Society for Medicinal Plant and ...
(Date:1/14/2014)... January 14, 2014 iLab Solutions, the leader ... the new Director of Product Strategy. In this role, Michelle ... iLab sub-teams to guide in the development of iLab products. ... the maximum possible benefit to the scientific community by offering ...
(Date:1/14/2014)... Mass. , Jan. 14, 2014  RXi Pharmaceuticals ... discovering, developing and commercializing innovative therapies addressing major ... that it received the Notice of Allowance from ... its unique self-delivering RNAi compounds (sd-rxRNA®), for the ...
(Date:1/14/2014)... 2014   Kinaxis ®, provider of RapidResponse ®, a ... operations planning ( S&OP ) service, is proud to be ... will be held at the Hilton San Diego Bayfront, January ... Elisabeth Kaszas , Director of Supply Chain at Amgen, ...
Breaking Biology Technology:World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... 26 Duska Therapeutics,Inc. (OTC Bulletin Board: DSKA.OB) ... information is available via Standard & Poor,s,Corporation Records ... full,description of Duska Therapeutics is published in the ... securities manual for secondary,trading in approximately 38 states ...
... in 21st ... ... in gene expression analysis-based diagnostics, is pleased to,announce that the company ... Dutch Innovation Platform.,MammaPrint, a 70-gene signature diagnostic test that predicts high ...
... FREMONT, Calif., June 26 ValGenesis, Inc., ... solutions, announced,the worldwide availability of ValGenesis 2.0, ... scalable validation life cycle,management and automation product., ... software suite can,efficiently manage the entire validation ...
Cached Biology Technology:Duska Therapeutics Obtains Standard & Poor's Listing 2Agendia's MammaPrint(R) Receives Prestigious Award From Dutch Innovation Platform 2Agendia's MammaPrint(R) Receives Prestigious Award From Dutch Innovation Platform 3ValGenesis, Inc. Announces Worldwide Release of Validation Life Cycle Management System - ValGenesis 2.0 2ValGenesis, Inc. Announces Worldwide Release of Validation Life Cycle Management System - ValGenesis 2.0 3
(Date:4/23/2014)... 23, 2014 A biomedical engineer at the University ... technology to make blood transfusions safer. His work is ... Institutes of Health (NIH). , Blood transfusions save ... modern medicine,s absolute necessities. Without them, for instance, routine ... are perfect, however. There,s strong evidence that transfusions of ...
(Date:4/23/2014)... leading a 2 million Food Standards Agency (FSA) project ... and industry workers. , Norovirus outbreaks can rapidly ... batch of frozen strawberries infected 11,000 people in Germany, ... of which strains cause infection and which foods are ... , Researchers will produce data that will help the ...
(Date:4/22/2014)... are all sorts of signaling strategies in nature. Peacocks ... satin bowbirds build specialized stick structures, called bowers, and ... bitterling males show off bright nuptial coloration during spawning ... communicate with others. , ... fitness implications for individuals that are either signaling or ...
Breaking Biology News(10 mins):UH biomedical engineer works to make blood transfusions safer 2UH biomedical engineer works to make blood transfusions safer 3Best practices in communication for the animal world 2Best practices in communication for the animal world 3
... been elected to Fellowship in the American Academy ... annually through a highly selective, peer-review process, based ... contributions that have advanced microbiology. There are now ... including basic and applied research, teaching, public health, ...
... underrepresented in the applicant pool for faculty positions in math, ... apply are interviewed and hired at rates equal to or ... the National Research Council. Similarly, women are underrepresented among ... tenure at the same or higher rates than men. ...
... KNOXVILLE -- As swine flu spread from Mexico to Texas ... began to alter their behavior. Families kept children home from ... of eating out. In so doing, the American population may ... How human behavior changes the spread of emerging infectious diseases, ...
Cached Biology News:Seventy-three scientists elected to the American Academy of Microbiology 2Seventy-three scientists elected to the American Academy of Microbiology 3Seventy-three scientists elected to the American Academy of Microbiology 4Women faring well in hiring process for science faculty jobs at research universities 2Women faring well in hiring process for science faculty jobs at research universities 3Women faring well in hiring process for science faculty jobs at research universities 4Scientists examine human behavior and the threat of disease 2
Purified anti-mouse Tim-1...
Biotin d anti-mouse Tim-1...
Mouse monoclonal [1-N-14] to Adenovirus Type 7 hexon C11 Immunogen: Purified Adenovirus type 7 Specificity: This antibody is specific for Adenovirus type 7 hexon C11....
Request Info...
Biology Products: